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Background. Fabry disease is an X-linked inherited disor-
der that is caused by excessive lysosomal globotriaosylceramide
(CTH) storage due to a deficiency in a-galactosidase A (a-Gal
A). Two recombinant enzyme preparations have been approved
as treatment modality. We studied emergence and properties of
a-Gal A antibodies in treated patients.
Methods. During the first 6 to 12 months of intravenous ad-
ministration of recombinant enzymes (rh-a-Gal A) formation
of antibodies was studied in 18 adult Fabry patients (two fe-
males).
Results. The female patients did not develop detectable
amounts of antibodies following enzyme therapy. After
6 months of treatment with either agalsidase alpha or beta, 11/16
male patients showed high titers of immunoglobulin G (IgG)
antibodies that cross-react in vitro similarly with both recom-
binant enzymes. The anti–rh-a-Gal A IgG neutralizes rh-a-Gal
A activity in vitro for 65% to 95%. During infusion with rh-
a-Gal A, circulating enzyme-antibody complexes are formed
and these complexes are taken up by leukocytes in the periph-
eral blood. After 6 months of treatment all IgG-negative pa-
tients showed a significant (P < 0.01) reduction of urinary CTH
(1890 ± 797 to 603 ± 291 nmol CTH/24hr urine), compared
to IgG-positive patients (mean increase from 2535 ± 988 to
2723 ± 1212), suggesting a negative effect of circulating anti-
bodies on renal tubular CTH clearance.
Conclusion. Emergence of antibodies with in vivo neutraliz-
ing capacities is frequently encountered in treated Fabry disease
patients. Complete cross-reactivity of these antibodies suggests
that it is unlikely that switching from one to the other recombi-
nant protein prevents the immune response and related effects.
Further studies on the clinical implications of a-Gal A antibod-
ies are essential.
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Recombinantly produced biological compounds are
increasingly used as treatment modality for diseases in
which symptoms or complications are due to the defi-
ciency of an enzyme or protein. Often these products have
to be administered life-long, such as administration of rh-
Epo for anemia in renal disease or rh-fVIII in hemophilia
A. Development of antibodies against administered re-
combinant proteins can occur and is well documented [1,
2]. Lysosomal storage disorders are characterized by the
deficiency of a lysosomal enzyme, which leads to the accu-
mulation of specific substrates, and subsequently causes
disease. There are about 60 known different lysosomal
storage disorders, each with its specific lysosomal enzyme
deficiency and characteristic clinical picture. Gaucher
disease, caused by deficiency of the lysosomal enzyme
b-glucocerebrosidase, was the first lysosomal storage dis-
order in which treatment with purified enzyme was shown
to be efficacious [3]. This approach has been copied for
other lysosomal storage disorders, such as Fabry disease
[4, 5], Pompe disease [6], and mucopolysaccharidosis type
I [7]. Fabry disease, caused by a deficiency of the lysoso-
mal enzyme a-galactosidase A (a-Gal A), leads to accu-
mulation of mainly globotriaosylceramide (CTH, Gb3)
in all cells of the body, but primarily endothelial cells
[8]. Other cells that accumulate CTH are myocytes, neu-
ronal cells, and in the kidney, besides endothelial cells,
podocytes and mesangial cells also store the lipid [9].
The continuous accumulation of glycosphingolipid leads
to several vascular complications, of which, apart from
stroke and cardiomyopathy, renal failure is a prominent
feature which often results in premature death. In a large
cohort of patients diagnosed with Fabry disease, 17% of
male patients suffered from end-stage renal failure, re-
quiring dialysis or renal transplantation [10]. In two clin-
ical trials with human recombinant a-galactosidase A,
promising improvement in renal pathology and stabiliza-
tion in renal function during 6 to 12 months of treatment
was observed [4, 5].
These studies led to the approval in Europe of two
enzyme preparations for the treatment of Fabry disease:
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agalsidase alpha (Replagal, TKT Corp., Cambridge, MA,
USA) and agalsidase beta (Fabrazyme, Genzyme Corp.,
Cambridge, MA, USA). In the United States only agal-
sidase beta has been approved. One of these two stud-
ies was performed with agalsidase alpha, which is pro-
duced in a continuous human cell line, and has been
studied at a dose of 0.2 mg/kg [5]. The other study was
performed with agalsidase beta, which is produced by
classical cDNA transduction in Chinese Hamster Ovary
(CHO) cells, and has been studied at a dose of 1.0 mg/kg
[4]. In Europe, physicians may find it difficult to de-
cide what treatment preparation to use because no direct
comparison studies have been performed to date. Both
enzymes have a terminal mannose-6-phosphate, and tar-
geting is therefore supposed to be at various cell types,
including endothelial cells. The formation of antibodies to
rh-a-Gal A as determined by enzyme-linked immunosor-
bent assay (ELISA) after six months of biweekly expo-
sure is reported as 3/14 in patients treated with 0.2 mg/kg
agalsidase alpha [5] versus 24/29 in patients treated with
1.0 mg/kg agalsidase beta [4]. The apparent difference in
prevalence of antibodies has been interpreted as pointing
to differences in composition of the two enzymes based
on their different production methods [11, 12].
The occurrence of antibodies results in hypersensitiv-
ity reactions in some patients, necessitating lengthening
of infusion time and/or the use of premedications such as
antihistamines or corticosteroids [4, 5]. The effect of an-
tibodies on rh-a-Gal A activity, cross-reactivity between
the two available enzyme preparations, and targeting af-
ter complex formation have so far not been investigated.
In this study we studied antibody formation in 18 patients
receiving either one of the two available enzyme prepa-
rations during the first 6 to 12 months.
METHODS
Patients
Patients that were referred to our hospital for treat-
ment with enzyme supplementation therapy and com-
pleted at least 6 months of treatment were included
in this study. Patients started treatment when they ful-
filled the Dutch criteria for initiation of treatment for
Fabry disease. These criteria require the presence of
chronic acroparesthesias, or cardiomyopathy, cerebral
infarctions, hearing loss, creatinine clearance, or a combi-
nation of these symptoms. Patients were treated with bi-
weekly agalsidase alpha (Replagal) at a dose of 0.2 mg/kg
(N = 7) or agalsidase beta (Fabrazyme) at a dose of
0.2 mg/kg (N = 6) or 1.0 mg/kg (N = 5). Agalsidase beta
0.2 mg/kg was given as part of another ongoing study.
Two patients were female. The diagnosis of Fabry dis-
ease was confirmed in all patients by demonstrating de-
ficient a-Gal A activity in leukocytes in male patients, or
a mutation of the a-Gal A gene in the female patients.
Four patients treated with 1.0 mg/kg agalsidase beta were
given premedication (1000 mg acetaminophen and 1 mg
clemastine) one hour before infusion. Patients who were
given a dose of 0.2 mg/kg agalsidase and one patient
receiving 1.0 mg/kg agalsidase beta did not use premedi-
cation. Patients who developed infusion-associated reac-
tions were treated with 5 mg dexamethasone orally one
hour before start of infusion. All patients gave informed
consent. Blood samples were taken pretreatment (t = 0)
and after 6 months (t = 6), and in some patients again
after 12 months of treatment (t = 12), and were spun
at 3000 rpm for 10 minutes. Serum was frozen at −20◦C
before use.
Purification of serum IgG
Prot A Sepharose (50 lL) was incubated with 50 lL of
serum for 60 minutes at room temperature. After spin-
ning, the immunoglobulin G (IgG)-depleted supernatant
was transferred and the remaining prot A Sepharose was
washed 3× with phosphate-buffered saline (PBS). Agal-
sidase alpha or beta in 0.1% bovine serum albumin (BSA)
was added to both the IgG-depleted supernatant and
the IgG-rich Sepharose-PBS mixture and incubated for
60 minutes at room temperature. Samples were spun, and
the enzyme activity in supernatant was determined.
Neutralization studies
Different volumes of serum (1 to 5 lL of serum, cor-
responding with a dilution of 1/25 to 1/5) were incubated
with either agalsidase alpha or beta. After 10 minutes of
incubation the enzymatic activity was determined.
Enzyme activity assays
The enzymatic activity of a-galactosidase A was mea-
sured as described elsewhere [13]. Briefly, 25 lL of
sample was incubated at 37◦C for 1 hour with 100 lL
reaction mixture containing 4-methylumbelliferyl-a-D-
galactopyranoside (4-MU-galactopyranoside; Sigma, St.
Louis, MO, USA) in a final concentration of 3.5 mmol/L in
100 mmol/L citrate/200 mmol/L phosphate buffer, pH 4.6.
N-acetylgalactosamine (100 mmol/L) was added to the
reaction mixture to inhibit a-N-acetyl-galactosaminidase
activity. Reactions were terminated by the addition of
2 mL 300 mmol/L glycine/NaOH buffer, pH 10.6, and
fluorescent 4-methyl-umbelliferone was measured with a
fluorimeter (Perkin-Elmer Corp., Norwalk, CT, USA) at
445 nm. To determine the enzyme activity in leukocytes,
the leukocyte pellet was sonicated twice in 200 lL wa-
ter for 10 seconds. Protein concentration of the sonicated
leukocytes was determined using a Lowry assay with hu-
man albumin as reference protein. Results are expressed
as nmol/mg protein/hr.
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ELISA for the detection of anti–rh-a-Gal A
IgG antibodies
Enzyme-linked immunosorbent assay (ELISA) plates
(96-well; Nunc, Maxisorp, Denmark) were coated
overnight at room temperature with l00 lL ∼11lg/L agal-
sidase alpha (Replagal, TKT, Inc., USA) or agalsidase
beta (Fabrazyme, Genzyme Corp., USA), which were ob-
tained from the local pharmacy. Plates were washed three
times with PBS and blocked with 100 lL/well 4% gelatin
for one hour. Subsequently, plates were washed 5× with
PBS/Tween 0.05% and incubated with 100 lL of serial
dilutions of serum in PBS for 1 hour under shaking condi-
tions. After washing peroxidase-labeled goat antihuman
IgG, antibody in PBS was added and left to incubate for 1
hour. After washing 100 lL 0.1 mg/mL tetramethyl ben-
zidine (TMB) in 0.11 mol/L, pH 5.5, NaAc and 0.003%
H2O2 were added and left to incubate for 30 minutes.
The colorimetric reaction was stopped by addition of 100
lL of H2SO4, and the absorbance was measured at 450
nm in a Titer-Tek multiscan ELISA reader (Titer-Tek,
Huntsville, AL, USA). The titer was determined by the
maximum dilution at which the postexposure serum had
an absorbance at least twice that of the baseline-sample
of that patient at the same dilution.
Detection of IgG-agalsidase complexes
From one patient (patient number 8) who was treated
with agalsidase beta, EDTA-anticoagulated blood was
taken at several time points during and after infusion
7 (before development of IgG) and 11 (after IgG anti-
bodies became detectable), respectively. Blood was spun
at 3000 rpm for 10 minutes, and plasma was stored at
−80◦C. Red cells were lysed using ammonium chloride,
and after washing with PBS, leukocyte pellets were stored
at −80◦C. Enzymatic activity was determined in plasma
and leukocytes as described. In addition, 10 lL plasma
was incubated with Prot A Sepharose or Sepharose-4B
beads for 60 minutes at room temperature. The sample
was spun and a-Gal A activity was measured in the su-
pernatant and the beads as described.
In vitro uptake of agalsidase alpha or beta
EDTA-anticoagulated blood was drawn from three
IgG-negative and one IgG-positive patient. Blood (2 mL,
containing between 20% to 35% lymphocytes and 4% to
9% monocytes) was incubated with 5 lg/mL agalsidase
beta or alpha for 120 minutes, shaking at 37◦C. After
60 minutes and 120 minutes, blood was spun. Supernatant
was harvested and stored at −20◦C. Red cells were lysed
using ammonium chloride, and after washing with PBS
leukocyte-pellets were stored at −20◦C. Enzyme activity
was performed as described.
Urinary CTH
In 11 patients, 24-hour urine was collected before
start and after 6 months of treatment for determina-
tion of globotriaosylceramide (CTH). From 6 patients
(two IgG-negative, four IgG-positive), 24-hour urine af-
ter 12 months of treatment was also available. Samples
were stored at −20◦C before use. Glycolipid was ex-
tracted from urinary sediment obtained after spinning
100 mL urine at 28,000g for 1 hour according to Folch
[14]. The chloroform phase was applied to a 500 mg
chloroform equilibrated LiChrolut RP18 column (Merck,
Whitehouse Station, NJ, USA). Bound glycolipids were
eluated with acetone:MetOH (9:1) v/v and dried under ni-
trogen. CTH was isolated on HPTLC (HP-TLC-silicagel
60) with development solvent of CHCl3/MetOH/H20
50/21/3 v/v/v. Lipids were identified with orcinol stain-
ing, and quantitated using reference standards by density
scanning (Scanning Quantity One, Bio-Rad Laborato-
ries, Inc., Hercules, CA, USA).
Statistical analysis
The Mann-Whitney U test was used to compare uri-
nary CTH levels between IgG-positive and IgG-negative
patients. Wilcoxon test was performed to compare uri-
nary CTH levels in individual patients before and after
6 months of treatment.
RESULTS
Patients
Characteristics of the patients are shown in Table 1.
Renal function of patients is shown in Table 1. Renal
function did not improve or deteriorate during treatment
period in all patients. Of the 18 patients treated, 11 devel-
oped an IgG antibody. The two female patients (patient 6
and 17) remained IgG-negative. Seven patients had infu-
sion related side effects, 3/5 treated with 1.0 mg/kg agal-
sidase beta, and 1/6 and 3/7 treated with 0.2 mg/kg agalsi-
dase beta and alpha, respectively. These side effects were
chills, fever (followed by acroparesthesias), and in one
patient, also nausea and vomiting. All patients with infu-
sion related events were IgG-positive. Two out of seven
patients required treatment with corticosteroids (5 mg
dexamathasone orally 1 hour before an infusion) to pre-
vent recurrence of chills. In other patients, chills were
transient or managed by reduction of infusion rate. There
was no correlation with genotype (either nonsense or mis-
sense mutation) and the development of IgG antibodies
(Table 1). Three patients (numbers 10, 11, and 15) with
a residual enzyme activity of 1.5 nmol/mg protein/hr or
higher did not develop anti–rh-a-Gal A antibodies.
Antibody titers and cross-reactivity
The titers of immunoreactivity toward either agalsi-
dase alpha or beta did not differ significantly for all sera
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Table 1. Characteristics of patients treated with agalsidase alpha or beta
Dose a-Gal-A 24-hr creatinine Anti –rh-a-
Patient Sex (mg/kg) Mutation act clearance Gal A IgG Side effects
1 M 0.2 beta F18S 0.3 113 – None
2 M 0.2 beta Q386X 0.4 97 + None
3 M 0.2 beta R220X 0 58 + None
4 M 0.2 beta IVS6-2(a-t) 0 56 + Chills on 1 occasion
5 M 0.2 beta R342Q 0.3 151 + None
6 F 0.2 beta 7299delT 16.1 116 – None
7 M 1.0 beta R342Q 0.1 64 + Chills and fever on a few occasions
8 M 1.0 beta W226X 0.3 121 + Chills and fever on a few occasions
9 M 1.0 beta 11051delAG 0 125 + Recurrent chills and fever,
premedication with dexamethasone
10 M 1.0 beta R112H 1.5 29 – None
11 M 1.0 beta N298S 2.4 29 – None
12 M 0.2 alpha R220X 0.4 127 + Recurrent chills and fever,
premedication with dexamethasone
13 M 0.2 alpha R220X 0 68 + Recurrent chills, stopped
treatment after 9 months
14 M 0.2 alpha R220X 0 41 – None
15 M 0.2 alpha D229E 1.5 Dialysis – None
16 M 0.2 alpha W226X 0.2 10 + Chills on 1 occasion
17 F 0.2 alpha R220X 11.3 83 – None
18 M 0.2 alpha R220X 1.2 130 + None
F denotes female patients. a-Gal A activity listed as nmol/mg protein/hr; beta refers to agalsidase beta (Fabrazyme); alpha refers to agalsidase alpha (Replagal).
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Fig. 1. Anti-agalsidase IgG titer in patients
treated with agalsidase alpha or beta. Open
bars represent titer to agalsidase beta, closed
bars to agalsidase alpha (normal <1:16).
(Fig. 1). All antibodies showed complete cross-reactivity;
patients who developed antibodies after intravenous
treatment with agalsidase alpha had the same titer toward
agalsidase beta and vice versa. Titers did not decline (de-
fined as a fourfold reduction or more) in four IgG-positive
patients that were monitored until month 12. In some pa-
tients there was a tendency in decline (titer reduction
between two- and fourfold). Treatment with dexametha-
sone in two patients showed no impact on titers up to
12 months.
Neutralizing capacity
All IgG-positive sera by ELISA showed a marked in
vitro inhibition of enzyme activity, ranging from 65% to
95%. There was no difference in inhibitory effect of raised
IgG antibodies between patients on agalsidase alpha or
beta (Fig. 2). Again, similar neutralizing activity of IgG
antibodies toward agalsidase beta in patients treated with
agalsidase alpha and vice versa was observed (Fig. 2).
Depleting sera of IgG by means of Prot A Sepharose
beads completely eliminated the inhibitory capacity of
serum, implicating that an IgG molecule is responsible
for the neutralizing effects of serum.
Effects of antibody formation on pharmacokinetics and
targeting in vivo and in vitro
Blood was drawn at various time points during an infu-
sion with agalsidase beta infusion both before (infusion
7) and after development of anti–rh-a-Gal A antibod-
ies (infusion 11). Incubation of the IgG-positive plasma
(from infusion 11) with Prot A Sepharose led to a de-
crease of up to 90% of plasma enzyme activity in the su-
pernatant. Incubation of IgG-negative plasma with Prot
A Sepharose did not result in loss of plasma enzyme
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activity (Fig. 3A). Enzyme activity was retrieved on the
Prot A sepharose beads (data not shown). Incubation
of IgG-positive plasma with Sepharose-4B beads did not
result in reduction of enzyme activity, excluding nonspe-
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out, and four patients with IgG antibodies during a 12-month treatment
period, demonstrating persistent urinary CTH clearance in two IgG-
negative patients, where no clearance is seen in IgG-positive patients
(B). Results expressed as mean ± SD.
cific binding of enzyme to the beads. This indicates, as
examined for agalsidase beta, that a major proportion of
circulating enzyme during an infusion is bound to IgG in
vivo in anti–rh-a-Gal A IgG-positive patients.
Incubation of 5 lg/mL agalsidase beta with EDTA-
anticoagulated whole blood obtained from an IgG-
positive patient before infusion 6 (Table 1, number 18)
showed markedly reduced plasma enzyme activity af-
ter 60 and 120 minutes, whereas three IgG-negative pa-
tients had high plasma enzyme activities (Fig. 4A). In
contrast, enzymatic activity in leukocytes taken from the
IgG-positive patient was markedly increased compared
to the IgG-negative patients (Fig. 4B), suggestive of in-
creased uptake of enzyme in leukocytes because of anti-
agalsidase IgG complexes.
Urinary CTH excretion
Mean urinary CTH levels at baseline did not differ sig-
nificantly between patients with and without IgG anti-
bodies, but were statistically different after 6 months of
treatment (P < 0.01, Fig. 5A). Mean urinary CTH levels
(nmol/24 hr urine) decreased in IgG-negative patients
(from 1890 ± 797 to 603 ± 291, P < 0.068) and increased
in IgG-positive patients (from 2535 ± 988 to 2723 ± 1212,
P = 0.49). The changes in urinary CTH did not differ
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between patients treated with agalsidase alpha or beta.
After 12 months of treatment, mean urinary CTH in two
IgG-negative patients remained low at 525 ± 508 nmol
CTH/24hr urine, whereas CTH remained high at 2964 ±
1257 nmol CTH/24hr urine in four IgG-positive patients
and showed no significant decline (Fig. 5B).
In the IgG-negative patients no difference was seen in
patients treated with agalsidase beta at a dose of 1.0 mg/kg
(N = 1), or the 0.2 mg/kg agalsidase alpha (N = 2) or beta
(N = 1). Renal function (as determined by 24-hour cre-
atinine clearance) did not show a correlation with CTH
levels (P = 0.52, r = 0.22) before start of therapy. Re-
nal function remained stable in all patients during the
study period, excluding the possibility that change in
CTH could be attributed to change in renal function.
DISCUSSION
This study shows that Fabry patients often develop anti-
bodies both toward agalsidase alpha and beta, that these
antibodies are cross-reactive, and that they have equal
neutralizing activity toward agalsidase alpha and beta.
Eleven out of 16 male patients (69%) developed IgG
antibodies within the first 6 months of treatment. Even
though the number of patients studied is limited, there
is no clear difference in the prevalence of antibodies be-
tween the two enzyme preparations.
Agalsidase alpha and beta are produced by different
methods. Agalsidase alpha is produced in a continuous
human cell line, whereas agalsidase beta is manufactured
by classic DNA recombinant technology in CHO cells.
There is currently much debate whether the difference
in production system causes different enzymes (e.g., with
regard to glycosylation), and subsequently a different re-
sponse in patients [12]. The present study shows that the
IgG antibodies that arise in patients treated with either
product are cross-reactive. This indicates that the im-
munogenicity of rh-a-Gal A in male patients with Fabry
disease is probably caused by an epitope that is evenly
expressed in both preparations. The absence of a clear
difference in prevalence of antibody formation and cross-
reactivity supports the supposition that these enzymes are
very similar.
The high prevalence of antibodies is probably due to
the fact that most male Fabry patients do not express
residual enzyme activity. This is in contrast with Gaucher
disease, as most Gaucher patients do have some residual
b-glucocerebrosidase activity. As a consequence, emer-
gence of antibodies against b-glucocerobrosidase is much
lower—of 1122 Gaucher patients treated with placental
derived b-glucocerobrosidase, only 142 (12.8%) patients
developed antibodies [15]. It is of interest to note that in
our study three male Fabry patients with a residual en-
zyme activity 1.5 nmol/mg prot/hr or higher did not de-
velop antibodies to the administered a-Gal A during the
first 6 months, nor did the two female patients. A larger
number of patients treated for a longer period of time
needs to be studied to see whether absence or presence
of significant residual enzyme activity plays an important
role in the development of antibodies.
The observation that all antibodies exhibit neutral-
izing capacities in vitro is in contrast with similar
studies on the treatment with recombinant enzyme in
Gaucher disease. In the aforementioned study, 10% of
the treated Gaucher patients with IgG antibodies toward
b-glucocerebrosidase showed inhibition of the enzymatic
reaction, with more than 50% [15]. There is one report
on enzyme neutralizing IgG antibody in Gaucher dis-
ease[16], although neutralizing effect, to some extent,
is seen in more patients. In our study, all patients with
antibodies showed inhibitory activity toward agalsidase.
Apparently there is a single highly immunogenic epitope
that has a close relation with the catalytic site, preventing
the enzymatic reaction to take place after binding of an
antibody on this epitope.
Whether inhibition of rh-a-Gal A activity by the IgG
antibodies has a significant clinical effect is unclear (see
also [17] for a general discussion on this issue). Pro-
longed treatment with agalsidase beta in patients who
had seroconverted did not show a CTH reaccumulation
in biopsied tissue of skin or kidney after 12 months of
treatment [4]. In addition, after one year there was no
evidence of immune complex depositions in the biop-
sied kidney tissue. However, the formation and binding
of antibodies can have consequences for the targeting
of rh-a-Gal A. Intravenously administered rh-a-Gal A
is taken up through the mannose-6-phosphate-receptor,
which is present on every cell. Antibody-antigen com-
plexes are taken up by mononuclear cells. Induction of
antibodies toward human rh-a-Gal A and subsequent
formation of circulating enzyme-antibody complex leads
to a significant uptake of enzyme by leukocytes. As a
consequence, less enzyme may be available for the en-
dothelial cells. We show that an increase of rh-a-Gal A up-
take in vitro in leukocytes was observed in a patient who
had developed antibodies, compared to three antibody-
negative patients. Though this experiment was carried
out in a patient treated with agalsidase beta, the com-
plete cross-reactivity of antibodies toward both prepara-
tions suggests this should also occur in patients treated
with agalsidase alpha. Diminished serum concentrations
of rh-a-Gal A after the development of IgG antibodies
have indeed been demonstrated in trials with both en-
zyme preparations [18, 19]. In trials with agalsidase beta,
reduced maximum concentrations (Cmax) and total area
under the curve (AUC) up to 26% of baseline values in
patients with the highest titers were noted. This might re-
sult in a less effective treatment compared to those who
are IgG-negative.
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This was confirmed in the present study, where IgG-
negative patients all showed urinary CTH clearance, in
contrast to only 2/7 of the IgG-positive patients. Urinary
CTH is believed to originate from shed renal tubular cells.
Recently, Thurberg et al confirmed that in Fabry disease
these cells, as well as podocytes, contain most CTH stor-
age in the kidney [9]. Interestingly, after 6 and 12 months
of treatment with 1.0 mg/kg rh-a-Gal A biweekly, renal
biopsies showed a decline in tubular CTH accumula-
tion for the whole group despite the presence of anti–
rh-a-Gal A antibodies [9]. Our results demonstrate that
development of IgG antibodies apparently results in di-
minished CTH clearance in these tubular cells. This sug-
gests that targeting of enzyme to the renal tubular cells is
decreased following seroconversion. The fact that in the
pivotal studies the majority of patients demonstrated a
decline in antibody titer after prolonged treatment seen
is reassuring but deserves further study [4, 5]. These re-
sults emphasize the need for further studies on antibody
formation and treatment efficacy in patients treated with
the two dosages currently used in daily practice [17].
CONCLUSION
This study shows that a high percentage of Fabry pa-
tients develop neutralizing IgG antibodies toward agal-
sidase alpha and beta. There is no clear difference in
immunogenicity of the two enzymes. In addition, anti-
bodies induced with agalsidase alpha or beta have equal
affinity for both enzymes in vitro. These findings support
an earlier study that suggested that at least the polypep-
tide moiety of both recombinant proteins is similar [20].
It seems therefore unlikely that switching from one prod-
uct to the other will evade antibody formation and related
side effects. The emergence of antibodies results in a less
decrease in urinary CTH compared to IgG-negative pa-
tients. No clear effect of antibody formation on creatinine
clearance was observed. Whether long-term efficacy of
ERT is hampered by these IgG antibodies is currently
unknown and should be carefully investigated.
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